Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
Evrysdi Debut Expands SMA Treatment Options, Improved Use Expected for All 3 Drugs: Professor
With the launch of Chugai Pharmaceutical’s Evrysdi (risdiplam), Japan now has three therapies available for the treatment of spinal muscular atrophy (SMA). While the new drug offers the first oral option for the rare genetic disease, a KOL in the…
To read the full story
Related Article
- Evrysdi Offers New Option for SMA Patients with Scoliosis: KOL
September 29, 2021
ACADEMIA
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
- NEJM Retracts Paper on Tavneos’ Pivotal Study
July 1, 2026
- Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
- Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…